. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Nov 1;55(3):330–335. doi: 10.1097/QAI.0b013e3181e583da

Table 4. Progression Rates based on presence of baseline risk factors.

CD4% <25%	HIV RNA >100,000 copies/ml	N =	% Progressed 1-Year^*	% Progressed 2-Years^*
no	no	55	11%	15%
no	yes	38	16%	21%
yes	no	39	14%	14%
yes	yes	60	29%	34%

Kaplan-Meir Product-Limit Survival Estimates